

Expanded View Figures




Figure EV2.

Figure EV2. Regulation of prominin2 by p38 MAPK.

- A Hs578 t cells were pretreated for 15 min with either EtOH or 10 μ M BIRB, followed by 60 min with either EtOH, 25 μ M 4HNE, 5 μ M RSL3, 4HNE, and BIRB or RSL3 and BIRB. Isolated protein was assessed by immunoblotting for prominin2, phospho-p38 (Thr180/Tyr182), and total p38. Shown is one replicate of three independent experiments ($n = 3$).
- B Hs578t cells were treated with RSL3 with either DMSO or 10 μ M BIRB. Cells were assessed for viability after 24 h. Absorbance was normalized to DMSO control. Shown are three independent replicates with standard deviation ($n = 3$ experiments per group). P -values were obtained by unpaired Student's t -test with $*P < 0.05$, $**P < 0.01$, $***P < 0.005$. Exact P -values are reported in Appendix Table S1.
- C MCF10A cells were pretreated for 15 min with either EtOH or 10 μ M BIRB, followed by 60 min with either EtOH or 10 μ M BIRB. Isolated protein was assessed by immunoblotting for prominin2 and β -tubulin expression. Shown is one replicate of three independent experiments ($n = 3$).
- D MCF10A cells were pretreated for 15 min with either DMSO or 10 μ M SB202190, followed by 60 min with either DMSO, 5 μ M RSL3, 10 μ M SB202190, or RSL3 and SB202190. mRNA was isolated and *PROM2* expression was quantified by qPCR. Shown are three independent experiments with standard deviation ($n = 3$ experiments per group). P -values were obtained by unpaired Student's t -test with $*P < 0.05$, $**P < 0.01$, $***P < 0.005$. Exact P -values are reported in Appendix Table S1.

Figure EV3. Increasing prominin2 expression protects against HSF1 inhibition.

- A Hs578 t cells were pretreated for 15 min with either EtOH or 10 μ M BIRB, followed by 60 min with either EtOH, 25 μ M 4HNE, 5 μ M RSL3, 4HNE, and BIRB or RSL3 and BIRB. Isolated protein was assessed by immunoblotting for prominin2, phospho-HSF1 (S326), total HSF1, phospho-p38 (Thr180/Tyr182), and total p38 expression. Shown is one replicate of three independent experiments ($n = 3$).
- B Hs578t cells were plated on slides pre-coated with laminin. Cells were treated for 60 min in either EtOH or 25 μ M 4HNE. Cells were stained for total HSF1 and counterstained with DAPI. Images were taken at 20 $\times$ magnification. Scale bar is 50 μ m. Shown is one replicate of three independent experiments ($n = 3$).
- C Cell lysates from MCF10A cells transfected with either the prominin2 expression construct or the vector control were assessed by immunoblotting for prominin2 and b-actin expression. Shown is one replicate of three independent experiments ($n = 3$).
- D MCF10A cells were transfected with either a prominin2 expression construct or a vector control prior to treatment with either DMSO, 10 μ M KRIBB11, RSL3, or KRIBB11 and RSL3 at the range of concentrations shown for 24 h, and the number of viable cells was quantified. Shown is representative experiment of three independent replicates ($n = 3$ experiments per group). Data are plotted as the mean $\pm$ SD. P -values were obtained by unpaired Student's t -test with $*P < 0.05$, $**P < 0.01$, $***P < 0.005$. Exact P -values are reported in Appendix Table S1.
- E siControl or siHSF1-treated MCF10A were maintained for 24 h in the presence of either DMSO, 2 μ M ferrostatin-1, 5 μ M RSL3, or ferrostatin-1, and RSL3, and the number of viable cells was quantified. Shown is representative experiment of three independent replicates ($n = 3$ experiments per group). Data are plotted as the mean $\pm$ SD. P -values were obtained by unpaired Student's t -test with $*P < 0.05$, $**P < 0.01$, $***P < 0.005$. Exact P -values are reported in Appendix Table S1.




Figure EV3.




Figure EV4. Additional data on pathway inhibition.

- A Hs578t cells were treated for 60 min with either EtOH, 25 μ M 4HNE, 5 μ M RSL3, 4HNE, and 10 μ M KRIBB11 or RSL3 and KRIBB11. Isolated protein was assessed by immunoblotting for prominin2, phospho-HSF1 (Ser326), total HSF1, phospho-p38 (Thr180/Tyr182), total p38, and β -actin expression. Shown is one replicate of three independent experiments ($n = 3$).
- B MCF10A cells were treated with either DMSO, 1 μ M IKE, IKE + 10 μ M KRIBB11, IKE + KRIBB11 + 2 μ M Fer-1, or IKE + KRIBB11 + 25 μ M ZVAD-fmk. Cells were assessed for viability after 24 h. Absorbance was normalized to DMSO control. Shown are four independent replicates with standard deviation ($n = 3$ experiments per group). P -values were obtained by unpaired Student's t -test with $*P < 0.05$, $**P < 0.01$, $***P < 0.005$. Exact P -values are reported in Appendix Table S1.
- C MCF10A cells were treated with RSL3 at the range of concentrations shown with either DMSO, 10 μ M BIRB, 10 μ M KRIBB11, 100 nM dasatinib, or 25 μ M erlotinib. Cells were assessed for viability after 24 h. Absorbance was normalized to DMSO control. Shown are three independent replicates with standard deviation ($n = 3$ experiments per group). P -values were obtained by unpaired Student's t -test with $*P < 0.05$, $**P < 0.01$, $***P < 0.005$. Exact P -values are reported in Appendix Table S1.
- D MCF10A cells were treated for 60 min with either DMSO or 10 μ M KRIBB11. mRNA was isolated, and *PROM2* expression was quantified by qPCR. Shown are three independent experiments with standard deviation ($n = 3$ experiments per group).
- E MCF10A cells were treated for 60 min with either DMSO or 10 μ M KRIBB11. mRNA was isolated, and *HSF1* expression was quantified by qPCR. Shown are three independent experiments with standard deviation ($n = 3$ experiments per group).
- F HMLE cells were treated with RSL3 at the range of concentrations shown in combination with either DMSO or 10 μ M KRIBB11. Cells were assessed for viability after 24 h (using crystal violet). Absorbance was normalized to DMSO control. Shown are three independent replicates with standard deviation ($n = 3$ experiments per group).
- G S1 cells were treated with RSL3 at the range of concentrations shown in combination with either DMSO or 10 μ M KRIBB11. Cells were assessed for viability after 24 h (using crystal violet). Absorbance was normalized to DMSO control. Shown are three independent replicates with standard deviation ($n = 3$ experiments per group).




Figure EV5. Acquired resistance to RSL3 can be overcome by HSF1 inhibition.

- A** MDA-MB-231 RSL3-sensitive cells were treated with RSL3 at the range of concentrations shown in combination with either DMSO or 10 μ M KRIBB11. Cells were assessed for viability after 24 h. Absorbance was normalized to DMSO control. Shown are three independent replicates with standard deviation ($n = 3$ experiments per group).
- B** MDA-MB-231 RSL3-resistant cells were treated with RSL3 at the range of concentrations shown in combination with either DMSO or 10 μ M KRIBB11. Cells were assessed for viability after 24 h. Absorbance was normalized to DMSO control. Shown are three independent replicates with standard deviation ($n = 3$ experiments per group). P -values were obtained by unpaired Student's t -test with $*P < 0.05$, $**P < 0.01$, $***P < 0.005$. Exact P -values are reported in Appendix Table S1.